Background: Patients with high-grade dysplasia (HGD) in Barrett’s oesophagus carry a significant risk of developing adenocarcinoma. Endoscopic mucosal resection (EMR) and photodynamic therapy (PDT) aim at the radical ablation of the dysplastic area. Methods: We used EMR to resect the macroscopic area of dysplastic mucosa followed by PDT to eliminate residual disease. PDT was performed after oral administration of 5-aminolevulinic acid (ALA, 40 mg/kg), using fractionated illumination 3 and 6 h later with 630 nm light at 100 J/cm2 through an endoscopic balloon diffuser. Results: We report 2 patients who developed adenocarcinoma shortly after incomplete endoscopic ablation of Barrett’s epithelium. In a 61-year-old man with HGD in 8-cm Barrett’s segment, HGD persisted 3 months after treatment. The oesophagectomy specimen showed a 2.3-cm pT2N0M0 adenocarcinoma in Barrett’s. In a 69-year-old woman with extensive HGD in 5-cm Barrett’s, HGD persisted after 3 PDT sessions in 1 year. Adenocarcinoma occurred 6 months after treatment. The oesophagectomy showed a pT1bN0M0 adenocarcinoma and extensive multifocal HGD in Barrett’s. Conclusions: The combination of EMR and PDT may be a promising option for local treatment of patients with HGD in Barrett’s oesophagus, provided all dysplastic tissue can be removed. Currently it should be offered only to patients who are willing to participate in a clinical trial with an intensive endoscopic follow-up programme.

1.
Levine DS: Management of dysplasia in the columnar-lined esophagus. Gastroenterol Clin North Am 1997;26:613–634.
2.
van den Boogert J, van Hillegersberg R, de Bruin RW, Tilanus HW, Siersema PD: Barrett’s oesophagus: Pathophysiology, diagnosis, and management. Scand J Gastroenterol 1998;33:449–453.
3.
van Sandick JW, Bartelsman JF, van Lanschot JJ, Tytgat GN, Obertop H: Surveillance of Barrett’s oesophagus: Physicians’ practices and review of current guidelines. Eur J Gastroenterol Hepatol 2000;12:111–117.
4.
Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O’Connell S, et al: Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology 2001;120:1607–1619.
5.
Edwards MJ, Gable DR, Lentsch AB, Richardson JD: The rationale for esophagectomy as the optimal therapy for Barrett’s esophagus with high-grade dysplasia. Ann Surg 1996;223:585–589.
6.
Ferguson MK, Naunheim KS: Resection for Barrett’s mucosa with high-grade dysplasia: Implications for prophylactic photodynamic therapy. J Thorac Cardiovasc Surg 1997;114:824–829.
7.
Heitmiller RF, Redmond M, Hamilton SR: Barrett’s esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Ann Surg 1996;224:66–71.
8.
Rice TW, Falk GW, Achkar E, Petras RE: Surgical management of high-grade dysplasia in Barrett’s esophagus. Am J Gastroenterol 1993;88:1832–1836.
9.
Zaninotto G, Parenti AR, Ruol A, Costantini M, Merigliano S, Ancona E: Oesophageal resection for high-grade dysplasia in Barrett’s oesophagus. Br J Surg 2000;87:1102–1105.
10.
Menke-Pluymers MB, Schoute NW, Mulder AH, Hop WC, van Blankenstein M, Tilanus HW: Outcome of surgical treatment of adenocarcinoma in Barrett’s oesophagus. Gut 1992;33:1454–1458.
11.
van Sandick JW, van Lanschot JJ, Kuiken BW, Tytgat GN, Offerhaus GJ, Obertop H: Impact of endoscopic biopsy surveillance of Barrett’s oesophagus on pathological stage and clinical outcome of Barrett’s carcinoma. Gut 1998;43:216–222.
12.
Morris CD, Byrne JP, Armstrong GR, Attwood SE: Prevention of the neoplastic progression of Barrett’s oesophagus by endoscopic argon beam plasma ablation. Br J Surg 2001;88:1357–1362.
13.
Bremner CG, Demeester TR: Proceedings from an international conference on ablation therapy for Barrett’s mucosa. Brittany, France, 31 August–2 September 1997. Dis Esophagus 1998;11:1–27.
14.
Byrne JP, Armstrong GR, Attwood SE: Restoration of the normal squamous lining in Barrett’s esophagus by argon beam plasma coagulation. Am J Gastroenterol 1998;93:1810–1815.
15.
van den Boogert J, van Hillegersberg R, Siersema PD, de Bruin RW, Tilanus HW: Endoscopic ablation therapy for Barrett’s esophagus with high-grade dysplasia: A review. Am J Gastroenterol 1999;94:1153–1160.
16.
Ell C, May A, Gossner L, Pech O, Gunter E, Mayer G, et al: Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett’s esophagus. Gastroenterology 2000;118:670–677.
17.
Soehendra N, Binmoeller KF, Bohnacker S, Seitz U, Brand B, Thonke F, et al: Endoscopic snare mucosectomy in the esophagus without any additional equipment: A simple technique for resection of flat early cancer. Endoscopy 1997;29:380–383.
18.
van Hillegersberg R, Kort WJ, Wilson JH: Current status of photodynamic therapy in oncology. Drugs 1994;48:510–527.
19.
Overholt BF, Panjehpour M: Photodynamic therapy in Barrett’s esophagus. J Clin Laser Med Surg 1996;14:245–249.
20.
Overholt BF, Panjehpour M: Photodynamic therapy for Barrett’s esophagus: Clinical update. Am J Gastroenterol 1996;91:1719–1723.
21.
van Hillegersberg R, Van den Berg JW, Kort WJ, Terpstra OT, Wilson JH: Selective accumulation of endogenously produced porphyrins in a liver metastasis model in rats. Gastroenterology 1992;103:647–651.
22.
Barr H, Shepherd NA, Dix A, Roberts DJ, Tan WC, Krasner N: Eradication of high-grade dysplasia in columnar-lined (Barrett’s) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 1996;348:584–585.
23.
Gossner L, Stolte M, Sroka R, Rick K, May A, Hahn EG, et al: Photodynamic ablation of high-grade dysplasia and early cancer in Barrett’s esophagus by means of 5-aminolevulinic acid. Gastroenterology 1998;114:448–455.
24.
Biddlestone LR, Barham CP, Wilkinson SP, Barr H, Shepherd NA: The histopathology of treated Barrett’s esophagus: Squamous reepithelialization after acid suppression and laser and photodynamic therapy. Am J Surg Pathol 1998;22:239–245.
25.
Guelrud M, Herrera I: Acetic acid improves identification of remnant islands of Barrett’s epithelium after endoscopic therapy. Gastrointest Endosc 1998;47:512–515.
26.
Van Laethem JL, Peny MO, Salmon I, Cremer M, Deviere J: Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett’s oesophagus. Gut 2000;46:574–577.
27.
Bonavina L, Ceriani C, Carazzone A, Segalin A, Ferrero S, Peracchia A: Endoscopic laser ablation of nondysplastic Barrett’s epithelium: Is it worthwhile? J Gastrointest Surg 1999;3:194–199.
28.
Krishnadath KK, Wang KK, Taniguchi K, Sebo TJ, Buttar NS, Anderson MA, et al: Persistent genetic abnormalities in Barrett’s esophagus after photodynamic therapy. Gastroenterology 2000;119:624–630.
29.
Ackroyd R, Brown N, Vernon D, Roberts D, Stephenson T, Marcus S, et al: 5-Aminolevulinic acid photosensitization of dysplastic Barrett’s esophagus: A pharmacokinetic study. Photochem Photobiol 1999;70:656–662.
30.
Haringsma J, Tytgat GN: The value of fluorescence techniques in gastrointestinal endoscopy: Better than the endoscopist’s eye? I: The European experience. Endoscopy 1998;30:416–418.
31.
Haringsma J, Tytgat GN, Yano H, Iishi H, Tatsuta M, Ogihara T, et al: Autofluorescence endoscopy: Feasibility of detection of GI neoplasms unapparent to white light endoscopy with an evolving technology. Gastrointest Endosc 2001;53:642–650.
32.
Ackroyd R, Brown NJ, Davis MF, Stephenson TJ, Marcus SL, Stoddard CJ, et al: Photodynamic therapy for dysplastic Barrett’s oesophagus: A prospective, double blind, randomised, placebo controlled trial. Gut 2000;47:612–617.
33.
van den Boogert J, van Staveren HJ, de Bruin RW, Eikelaar JH, Siersema PD, van Hillegersberg R: Photodynamic therapy for esophageal lesions: Selectivity depends on wavelength, power, and light dose. Ann Thorac Surg 1999;68:1763–1769.
34.
van den Boogert J, van Hillegersberg R, van Staveren HJ, de Bruin RW, van Dekken H, Siersema PD, et al: Timing of illumination is essential for effective and safe photodynamic therapy: A study in the normal rat oesophagus. Br J Cancer 1999;79:825–830.
35.
Panjehpour M, Overholt BF, Haydek JM, Lee SG: Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett’s esophagus and effect of oral steroids on stricture formation. Am J Gastroenterol 2000;95:2177–2184.
36.
May A, Gossner L, Pech O, Fritz A, Gunter E, Mayer G, et al: Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett’s oesophagus: Acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol 2002;14:1085–1091.
37.
van Sandick JW, Bartelsman JF, van Lanschot JJ, Tytgat GN, Obertop H: Surveillance of Barrett’s oesophagus: Physicians’ practices and review of current guidelines. Eur J Gastroenterol Hepatol 2000;12:111–117.
38.
van Sandick JW, van Lanschot JJ, ten Kate FJ, Offerhaus GJ, Fockens P, Tytgat GN, et al: Pathology of early invasive adenocarcinoma of the esophagus or esophagogastric junction: Implications for therapeutic decision making. Cancer 2000;88:2429–2437.
39.
Holscher AH, Bollschweiler E, Bumm R, Bartels H, Hofler H, Siewert JR: Prognostic factors of resected adenocarcinoma of the esophagus. Surgery 1995;118:845–855.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.